{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:35:38Z","timestamp":1790778938684,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673518"],"award-info":[{"award-number":["81673518"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:p>\n                    An outbreak of 2019\u2010nCoV infection has spread across the world. No specific antiviral drugs have been approved for the treatment of COVID\u20102019. In addition to the recommended antiviral drugs, such as interferon\u2010\u0251, lopinavir\/ritonavir, ribavirin, and chloroquine phosphate, some clinical trials focusing on virus RNA\u2010dependent RNA polymerase (RdRp) inhibitors have been registered and initiated. Favipiravir, a purine nucleic acid analog and potent RdRp inhibitor approved for use in influenza, is also considered in several clinical trials. Herein, we summarized the pharmacokinetic characteristics of favipiravir and possible drug\u2013drug interactions from the view of drug metabolism. We hope this will be helpful for the design of clinical trials for favipiravir in COVID\u20102019, as data regarding\n                    <jats:italic>in vitro<\/jats:italic>\n                    virus inhibition and efficacy in preclinical animal studies are still not available.\n                  <\/jats:p>","DOI":"10.1002\/cpt.1844","type":"journal-article","created":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T12:25:40Z","timestamp":1586003140000},"page":"242-247","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":310,"title":["Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019\u2010nCoV Infection"],"prefix":"10.1111","volume":"108","author":[{"given":"Yin\u2010Xiao","family":"Du","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology Xiangya Hospital Central South University Changsha Hunan China"},{"name":"Institute of Clinical Pharmacology Hunan Key Laboratory of Pharmacogenetics Central South University Changsha Hunan China"},{"name":"National Clinical Research Center for Geriatric Disorders Xiangya Hospital Central South University Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao\u2010Ping","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Xiangya Hospital Central South University Changsha Hunan China"},{"name":"Institute of Clinical Pharmacology Hunan Key Laboratory of Pharmacogenetics Central South University Changsha Hunan China"},{"name":"National Clinical Research Center for Geriatric Disorders Xiangya Hospital Central South University Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"key":"e_1_2_10_1_1","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202000047"},{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00016-0"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.5582\/ddt.2020.01012"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.93.027"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.981-986.2005"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001967"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw571"},{"key":"e_1_2_10_8_1","unstructured":"Zhou P.et al.Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv.https:\/\/doi.org\/10.1038\/s41586\u2010020\u20102012\u20107. [e\u2010pub ahead of print]."},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30251-8"},{"key":"e_1_2_10_11_1","article-title":"Experimental treatment with Favipiravir for COVID\u201019: an open\u2010label control study","author":"Cai Q.","journal-title":"Engineering"},{"key":"e_1_2_10_12_1","doi-asserted-by":"crossref","unstructured":"Chen C.et al.Favipiravir versus arbidol for COVID\u201019: a randomized clinical trial. bioRxiv preprint.https:\/\/doi.org\/10.1101\/2020.03.17.20037432. [e\u2010pub ahead of print].","DOI":"10.1101\/2020.03.17.20037432"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0364-1"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)71047-3"},{"key":"e_1_2_10_15_1","unstructured":"Japanese Pharmaceuticals and Medical Devices Agency (PMDA).Report on the Deliberation Results [Internet]<https:\/\/www.pmda.go.jp\/files\/000210319.pdf> (2014)."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-37866-z"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01305-16"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005389"},{"key":"e_1_2_10_19_1","article-title":"Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection","author":"Wang Y.","journal-title":"J. Infect. Dis."},{"key":"e_1_2_10_20_1","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus\u2013infected pneumonia in Wuhan, China","author":"Wang D.C.","journal-title":"JAMA"},{"key":"e_1_2_10_21_1","article-title":"Clinical characteristics of 2019 novel coronavirus infection in China","author":"Guan W.C.","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12644"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003260336"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498250210158221"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.05.011"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(98)00008-2"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498250210158915"},{"key":"e_1_2_10_28_1","first-page":"251","article-title":"Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver","volume":"23","author":"Clarke S.E.","year":"1995","journal-title":"Drug Metab. Dispos."},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00875"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.1844","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1844","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.1844","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T08:37:43Z","timestamp":1699346263000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.1844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1002\/cpt.1844"],"URL":"https:\/\/doi.org\/10.1002\/cpt.1844","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"assertion":[{"value":"2020-03-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}